Last reviewed · How we verify

Travoprost/ Timolol/ Azopt/ Brimonidine

Singapore Eye Research Institute · Phase 3 active Small molecule

Travoprost/ Timolol/ Azopt/ Brimonidine is a Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist Small molecule drug developed by Singapore Eye Research Institute. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.

Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma, Ocular hypertension.

At a glance

Generic nameTravoprost/ Timolol/ Azopt/ Brimonidine
SponsorSingapore Eye Research Institute
Drug classProstaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist
TargetProstaglandin F2α receptor, Beta-adrenergic receptor, Carbonic anhydrase, Alpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Travoprost, Timolol, Azopt, and Brimonidine work together to reduce intraocular pressure in patients with glaucoma or ocular hypertension. By increasing uveoscleral outflow and decreasing aqueous humor production, these medications help to alleviate symptoms and slow disease progression. The combination of these mechanisms provides a comprehensive approach to managing glaucoma and ocular hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Travoprost/ Timolol/ Azopt/ Brimonidine

What is Travoprost/ Timolol/ Azopt/ Brimonidine?

Travoprost/ Timolol/ Azopt/ Brimonidine is a Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist drug developed by Singapore Eye Research Institute, indicated for Glaucoma, Ocular hypertension.

How does Travoprost/ Timolol/ Azopt/ Brimonidine work?

Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

What is Travoprost/ Timolol/ Azopt/ Brimonidine used for?

Travoprost/ Timolol/ Azopt/ Brimonidine is indicated for Glaucoma, Ocular hypertension.

Who makes Travoprost/ Timolol/ Azopt/ Brimonidine?

Travoprost/ Timolol/ Azopt/ Brimonidine is developed by Singapore Eye Research Institute (see full Singapore Eye Research Institute pipeline at /company/singapore-eye-research-institute).

What drug class is Travoprost/ Timolol/ Azopt/ Brimonidine in?

Travoprost/ Timolol/ Azopt/ Brimonidine belongs to the Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist class. See all Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist drugs at /class/prostaglandin-analogue-beta-blocker-carbonic-anhydrase-inhibitor-alpha-2-adrenergic-agonist.

What development phase is Travoprost/ Timolol/ Azopt/ Brimonidine in?

Travoprost/ Timolol/ Azopt/ Brimonidine is in Phase 3.

What are the side effects of Travoprost/ Timolol/ Azopt/ Brimonidine?

Common side effects of Travoprost/ Timolol/ Azopt/ Brimonidine include Headache, Eye pain, Blepharitis, Dry mouth, Dizziness.

What does Travoprost/ Timolol/ Azopt/ Brimonidine target?

Travoprost/ Timolol/ Azopt/ Brimonidine targets Prostaglandin F2α receptor, Beta-adrenergic receptor, Carbonic anhydrase, Alpha-2 adrenergic receptor and is a Prostaglandin analogue, Beta blocker, Carbonic anhydrase inhibitor, Alpha-2 adrenergic agonist.

Related